SARAH LOSS: Open Payments
NPI 1295265635 · AMHERST, NY. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,562 in 132 payments from 18 companies in 2025. Trend: 2023 $1,544 · 2024 $4,479 · 2025 $2,562
Food & beverage: $2,562
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 18 | $482 |
| Teva Pharmaceuticals USA, Inc. | 24 | $420 |
| Neurocrine BioSciences, Inc. | 17 | $374 |
| Otsuka America Pharmaceutical, Inc. | 13 | $277 |
| Lundbeck LLC | 16 | $198 |
| Takeda Pharmaceuticals U.S.A., Inc. | 11 | $137 |
| Janssen Pharmaceuticals, Inc | 7 | $130 |
| Vanda Pharmaceuticals Inc. | 5 | $106 |
| Axsome Therapeutics, Inc. | 5 | $100 |
| Bausch Health US, LLC | 4 | $90 |
Products named: CAPLYTA, INGREZZA, REXULTI, UZEDY, AUSTEDO XR, SPRAVATO, ABILIFY ASIMTUFII, FANAPT.
Industry payments across NY — which companies pay providers there.
